Gene Biotherapeutics, Inc.
Other OTCTotal Valuation
Gene Biotherapeutics, Inc. carries a market capitalization of 6,493.00, placing it among publicly traded companies globally. Its enterprise value stands at 864,983.09, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6,493.00 |
| Enterprise Value | 864,983.09 |
Share Statistics
Gene Biotherapeutics, Inc. currently has 40.33M shares outstanding.
| Shares Outstanding | 40.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Gene Biotherapeutics, Inc. trades at a trailing price-to-earnings ratio of 2.60.
| PE Ratio | 2.60 |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | -0.15 |
| P/FCF Ratio | -1.58 |
| P/OCF Ratio | -0.60 |
Financial Position
Gene Biotherapeutics, Inc. maintains a current ratio of 0.08, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -27.59, indicating conservative leverage, while an interest coverage ratio of -21.96 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.08 |
| Quick Ratio | 0.08 |
| Debt / Equity | -27.59 |
| Debt / EBITDA | -1.00 |
| Interest Coverage | -21.96 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -171.94 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -2.89 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Income Statement
EBITDA reached -1.26M, while operating income came in at -1.26M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.26M |
| Pretax Income | -651,550.00 |
| Net Income | -517,896.00 |
| EBITDA | -1.26M |
| EBIT | -1.26M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
Gene Biotherapeutics, Inc. holds 386,027.00 in cash and equivalents against 1.26M in total debt, resulting in a net debt position of 724,312.00. Total book value stands at -119.43M, with working capital of -4.62M providing operational flexibility.
| Cash & Cash Equivalents | 386,027.00 |
| Total Debt | 1.26M |
| Net Debt | 724,312.00 |
| Equity (Book Value) | -119.43M |
| Book Value Per Share | -6.64 |
| Working Capital | -4.62M |
Cash Flow
Gene Biotherapeutics, Inc. produced -1.13M in operating cash flow over the past twelve months. After subtracting -4.00 in capital expenditures, free cash flow totaled -1.13M - equivalent to -0.06 per share.
| Operating Cash Flow | -1.13M |
| Capital Expenditures | -4.00 |
| Free Cash Flow | -1.13M |
| FCF Per Share | -0.06 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -222.68 |
| FCF Yield | -63.31 |
Stock Splits
Gene Biotherapeutics, Inc.'s most recent stock split took place on July 18, 2013 with a 20:1 split ratio.
| Last Split Date | 7/18/2013 |
| Split Ratio | 20:1 |
Scores
Gene Biotherapeutics, Inc. posts an Altman Z-Score of -311.94, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -311.94 |